Evarrest Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high surgical bleeding complications, limitations of traditional suturing methods, early adoption of fibrin sealants, increasing surgical volumes, need for faster intraoperative bleeding control.

The growth in the forecast period can be attributed to growth in complex surgical procedures, rising trauma incidence, expanding hospital infrastructure, increasing surgeon preference for sealant patches, technological advances in surgical biomaterials. Major trends in the forecast period include rising demand for rapid surgical hemostasis, increased use of ready-to-use hemostatic patches, growth in emergency and trauma surgeries, preference for no-preparation bleeding control solutions, expansion of advanced surgical care infrastructure.

The increasing number of surgical procedures is expected to drive the growth of the evarrest market in the coming years. Surgical procedures are medical operations or interventions performed by surgeons to treat, diagnose, or prevent conditions, injuries, or diseases. The rise in surgical procedures is driven by an aging population and advancements in medical technology, which have made surgeries safer and more widely accessible. Evarrest is used during surgical procedures by applying its fibrin sealant patch to bleeding sites, where it promotes rapid clot formation to effectively control bleeding. For example, in December 2023, the UK Health Security Agency, a UK-based government body, reported that coronary artery bypass graft surgeries increased to 27,524 procedures in 2023 compared to previous years. Therefore, the growing number of surgical procedures is fueling the expansion of the evarrest market.

Rising healthcare expenditure is also expected to support the growth of the evarrest market. Healthcare expenditure encompasses total spending on medical services, preventive care, medications, and health-related activities to maintain or improve population health. Growth in healthcare spending is driven by aging populations that require more medical care and by advancements in technology, which increase treatment costs. Higher healthcare expenditure supports the adoption of Evarrest by enabling investment in advanced medical technologies that improve surgical outcomes and reduce complications. For example, in December 2024, the Centers for Medicare & Medicaid Services (CMS), a US federal agency, reported that healthcare spending in the US increased by 7.5% in 2023, reaching $4.9 trillion, up from a 4.6% increase in 2022. Therefore, rising healthcare expenditure is driving the growth of the evarrest market.

The growing adoption of personalized medicine is also anticipated to propel the evarrest market in the future. Personalized medicine refers to treatments tailored to an individual’s genetic profile, lifestyle, and specific health conditions, aiming to deliver more precise and effective care. The rise in personalized medicine adoption is driven by its ability to provide targeted treatments with improved outcomes and fewer side effects. For Evarrest, personalized medicine involves tailoring its application based on patient-specific factors, such as genetic traits or clotting disorders, to enhance treatment safety and efficacy. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six approvals in 2022. Therefore, the increasing adoption of personalized medicine is supporting the growth of the evarrest market.

Major companies operating in the evarrest market are Johnson & Johnson.

North America was the largest region in the evarrest market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the evarrest market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the evarrest market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the evarrest market by raising costs associated with importing human plasma derivatives, medical-grade biomaterials, and specialized manufacturing equipment. These impacts are most evident in hospital-based surgical settings across regions reliant on imported biologic products, including parts of europe and asia pacific. Increased production costs can affect procurement decisions and surgical budgets. However, tariffs are also driving investments in local manufacturing and improved supply chain resilience for surgical hemostatic solutions.

The evarrest market research report is one of a series of new reports that provides evarrest market statistics, including evarrest industry global market size, regional shares, competitors with a evarrest market share, detailed evarrest market segments, market trends and opportunities, and any further data you may need to thrive in the evarrest industry. This evarrest market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Evarrest is an FDA-approved fibrin sealant patch designed to manage bleeding during surgeries, consisting of a flexible composite patch coated with human fibrinogen and thrombin to promote rapid clotting. It is particularly beneficial in emergency situations, requiring no preparation and effectively stopping bleeding on the first attempt.

The main types of indications for evarrest are surgical procedures and trauma cases. Surgical procedures are medical interventions performed to treat, diagnose, or prevent conditions, ranging from minor to complex operations. These products can come in various forms, including powder and pre-mixed solutions, and are distributed through hospitals, pharmacies, and online platforms.

The evarrest market consists of sales of products including the evarrest fibrin sealant patch, surgical powder absorbable hemostat, surgiflo hemostatic matrix, harmonic devices, and endopath products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.